By LSE RNS
Sinclair Pharma plc
Publication of Annual Report and Accounts
London, 30 March 2017 Sinclair Pharma plc (SPH.L), ("Sinclair" or the "Company") the international aesthetics company, announces that its Annual Report and Accounts for the year ended 31 December 2016 is available at the Company's website, www.sinclairpharma.com and will be posted to shareholders shortly.
For further information please contact:
Sinclair Pharma plc |
Tel: +44 (0) 20 7467 6920 |
Chris Spooner |
|
|
|
Peel Hunt LLP (NOMAD and Joint Broker) |
Tel: +44 (0) 20 7418 8900 |
James Steel |
|
|
|
|
|
RBC Capital Markets (Joint Broker) |
Tel: +44 (0) 20 76534000 |
Marcus Jackson |
|
|
|
|
|
Media enquiries |
|
FTI Consulting |
Tel: +44 (0) 203 727 1000 |
Ben Atwell |
|
Notes to Editors:
About Sinclair Pharma plc
Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors. For more information, please visit www.sinclairpharma.com
You are here: news > regulatory news